A Bluebird Bio gene therapy that treats the rare blood disorder beta thalassemia is now approved by the FDA, providing the option for a one-time treatment that could eliminate the need for regular blood transfusions patients undergo as the current standard of care.
Somerville, Massachusetts-based Bluebird set a $2.8 million wholesale price for the product, Zynteglo, making it one of the most expensive therapies to reach the market. But the biotech said Wednesday that it has also come up with a reimbursement strategy that is tied to patients achieving benefit from the therapy.
Beta thalassemia is an inherited blood disorder that leads to lower levels of hemoglobin, the oxygen-carrying protein in red blood cells. The resulting low levels of oxygen in the body leads to dizziness, weakness, fatigue, and bone problems, among other complications.
Click here to read the full article at MedCityNews
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.
BioPharma Global is a mission-driven corporation dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with unmet medical needs. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.